Mihir Jain: Can Gene Therapy Transform Hemophilia Care in India?
Mihir Jain, MBBS graduate from Government Medical College and Hospital (GMCH), Chandigarh, shared a post on LinkedIn:
“Can gene therapy transform hemophilia care in India?
I recently completed an independent healthcare strategy project exploring the commercial and market access landscape for hemophilia gene therapy in India.
The project combines my medical background with data-driven analysis to evaluate:
- Market opportunity
- Patient population and treatment landscape
- Access and reimbursement challenges
- Competitive environment
- Strategic considerations for commercialization
The project includes:
As an MBBS graduate, I’m building a portfolio at the intersection of healthcare consulting, life sciences strategy, medical affairs, pharmacovigilance, and data analytics by tackling real-world industry questions.
I welcome feedback and would be glad to connect with professionals working in healthcare consulting, pharma, biotech, and life sciences.”
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 03:19Where Does Stroke Treatment Go Next on The Latest ESOC 2026 TV Studio Session – ESO
-
Jul 21, 2026, 03:09Francesca Palandri: New Insights Into Anemia Management in Myelofibrosis
-
Jul 21, 2026, 01:57A New Approach to Understanding Plasmin Generation and Fibrinolysis – RPTH Journal
-
Jul 21, 2026, 01:52Maria Diaz Alonso: Delivering My First International Oral Presentation at ISTH 2026
-
Jul 21, 2026, 01:44Megan Preece: Presenting New Research on Antiphospholipid Syndrome at ISTH 2026
-
Jul 21, 2026, 01:28Dhamirah Nazihah Mohd Nasiruddin: A Milestone in My Haemostasis and Thrombosis Journey at ISTH 2026
-
Jul 21, 2026, 00:55Anita Brikman on PPTA’s First-Half 2026 Achievements
-
Jul 21, 2026, 00:50Caitlin Raymond: Can Therapeutic Plasma Exchange Reduce Microplastics?
-
Jul 21, 2026, 00:46Yohei Hisada: Science, Collaboration, and New Beginnings at ISTH 2026